SequelSEC

Dianthus Therapeutics, Inc. /DE/ DNTH

Pharmaceutical Preparations · CIK 0001690585 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.04M
Fiscal year ended 2025-12-31
Operating income
-$177.93M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $2.04M and net income of -$162.34M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Dianthus Therapeutics, Inc. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Dianthus Therapeutics, Inc. /DE/ income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$2.04M$6.24M$2.83M$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$177.93M-$101.86M-$48.17M-$82.97M-$59.96M-$35.73M-$9.27M
Net income-$162.34M-$84.97M-$43.56M-$76.77M-$57.52M-$35.49M-$9.43M
Research & development$145.64M$83.10M$32.84M$59.21M$41.34M$27.90M$5.78M
Weighted-average diluted sharesshares 38.62Mshares 33.31Mshares 5.15MUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0
Diluted EPS$-4.20$-2.55$-8.45UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$34.33M$24.99M$18.16M$23.76M$18.62M$7.83M$3.49M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Dianthus Therapeutics, Inc. /DE/ balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$51.09M$22.79M$132.32M$65.07M$58.34M$51.40M$4.51M
Total assets$530.92M$374.01M$179.40M$161.51M$157.31M$54.46MUnavailable
Current assets$409.44M$280.90M$177.45M$149.84M$145.32M$52.50MUnavailable
Total liabilities$37.52M$21.53M$10.54M$20.32M$11.66M$4.14MUnavailable
Current liabilities$30.73M$18.45M$9.63M$14.12M$10.42M$4.14MUnavailable
Total equity incl. NCI$493.40M$352.48M$168.87M$141.19M$145.65M-$42.12M-$8.87M
Temporary (mezzanine) equityUnavailableUnavailable$0$0Unavailable$92.44M$17.92M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$52.00K$0$294.00KUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$9.72M$4.58M$2.61M$2.81M$3.49M$167.00KUnavailable

Cash flow

Dianthus Therapeutics, Inc. /DE/ cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$129.06M-$78.18M-$36.86M-$57.10M-$41.89M-$22.26M-$6.53M
Capital expendituresUnavailableUnavailableUnavailable$3.06M$7.67M$2.20M$139.00K
Investing cash flow-$122.83M-$286.81M$20.25M$1.53M-$91.70M-$2.20M-$139.00K
Financing cash flow$280.12M$255.62M$133.57M$62.30M$142.15M$71.49M$10.71M
Net change in cash$28.23M-$109.37M$116.97M$6.73M$8.56M$47.02M$4.04M
Stock-based compensation$22.79M$12.89M$2.90M$10.00M$10.70M$2.26M$662.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable$1.84M$875.00K$376.00K$6.00K

Derived

Dianthus Therapeutics, Inc. /DE/ derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailable-$60.16M-$49.56M-$24.46M-$6.67M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-8739.3%-1633.7%-1704.7%UnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue1119.5%206.8%102.6%UnavailableUnavailableUnavailableUnavailable
Current ratio13.32x15.22x18.42x10.62x13.95x12.68xUnavailable
Revenue YoY growth-67.3%120.6%UnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-7973.3%-1362.8%-1541.2%UnavailableUnavailableUnavailableUnavailable
R&D / revenue7153.1%1332.9%1162.1%UnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DNTH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.